Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer

Next Previous
Trial Profile

A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms DESTINY-CRC01
  • Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc

    • Most Recent Events

    • 31 Aug 2023 According to a Daiichi Sankyo Company media release, ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designations in U.S for the treatment of patients with HER2 positive (IHC 3+) metastatic colorectal cancer who have received two or more prior regimens, based on final results from the DESTINY-CRC01 and primary results from the DESTINY-CRC02 trial.
    • 22 Jan 2022 Results (Data cut off date: Dec 28, 2020) assessing the updated longer-term efficacy and safety data of T-DXd in pts with HER2-expressing mCRC showed promising antitumor activity and a manageable safety profile (cohort A median follow-up [FU], presented at the 2022 Gastrointestinal Cancers Symposium.
    • 07 Sep 2021 According to a Daiichi Sankyo Company media release, the company will hold a conference call for investors and analysts on September 21, 2021 to provide an overview of the ESMO data.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top